Using Hizentra® for treating Chronic Inflammatory Demyelinating Polyneuropathy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The pHeNIx study is a national multicentre observational study aimed at understanding the use of Hizentra® in patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). It focuses on the transition from intravenous immunoglobulin (IVIg) to subcutaneous immunoglobulin (SCIg) treatment, assessing tolerability and efficacy through patient-reported outcomes. The study seeks to gather real-world data on the characteristics of patients receiving this treatment and the methods for switching routes of administration.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adult patient (aged ≥18 years)
* Patients suffering from CIDP according to EAN/PNS 2021 criteria
* Planned switch from IVIg to Hizentra®
* Patient treated with at least 3 courses of IV immunoglobulin and deemed by the investigator to be dependent on immunoglobulins
* Patient deemed to be stable, with no change in their treatment for the disease during the 3 months prior to inclusion
* Patients who have a smartphone, a tablet or a computer
* Patients who have been informed verbally and in writing of the purposes of the study

Exclusion Criteria:

* Concomitant participation in an interventional clinical study

Where it's running

• CHU Angers
  Angers, France Recruiting
• Hôpital privé de La Casamance
  Aubagne, France Recruiting
• CH Bayonne
  Bayonne, France Recruiting
• Hôpital Pellegrin
  Bordeaux, France Recruiting
• CHRU Brest
  Brest, France Recruiting
• Hôpital Henri Mondor
  Créteil, France Recruiting

Study contacts

• Study coordinator: Trial Registration Coordinator
• Email: clinicaltrials@cslbehring.com
• Phone: +1 610-878-4697

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• KITE-363 treatment for relapsed or refractory autoimmune neurologic diseases

  This study will test whether KITE-363 is safe and can help people with relapsed or treatment-resistant autoimmune neurologic diseases such as MS, CIDP, and myasthenia gravis.

  Recruiting at 10 sites Phase 1 Gilead Sciences · Newport Beach, California and 9 other locations · NCT07304154

• Immunoadsorption treatment for chronic inflammatory demyelinating polyneuropathy

  This observational study will try immunoadsorption as a next-step treatment for adults with CIDP who do not respond well to IVIg or methylprednisolone.

  Recruiting University of Ulm · Ulm, Baden-Wurttemberg · NCT07154524

• Empasiprubart for adults with CIDP

  This study will test whether IV empasiprubart helps improve symptoms and is safe for adults with CIDP, with an initial 24-week randomized comparison to placebo followed by two years of empasiprubart for all participants.

  Recruiting at 94 sites Phase 3 argenx · Birmingham, Alabama and 93 other locations · NCT07091630

• Imeroprubart for adults with CIDP

  This study will test whether the monoclonal antibody Imeroprubart helps adults with active CIDP who are already on stable immunoglobulin or corticosteroid treatment.

  Recruiting at 117 sites Phase 2 Immunovant Sciences GmbH · Tucson, Arizona and 141 other locations · NCT07032662

• Empasiprubart versus IVIg for treating CIDP in adults

  This trial tests whether empasiprubart works as well as IVIg and is safe for adults with CIDP who currently benefit from IVIg.

  Recruiting at 107 sites Phase 3 argenx · Birmingham, Alabama and 106 other locations · NCT06920004

• Evaluating DNTH103 for treating chronic inflammatory demyelinating polyneuropathy

  This study is testing a new treatment called DNTH103 to see if it can help adults with chronic inflammatory demyelinating polyneuropathy feel better and stay safe.

  Recruiting at 201 sites Phase 3 Dianthus Therapeutics · Birmingham, Alabama and 200 other locations · NCT06858579

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.